Zobrazeno 1 - 10
of 273
pro vyhledávání: '"Begoña Mellado"'
Autor:
Vicenç Ruiz de Porras, Adrià Bernat-Peguera, Clara Alcon, Fernando Laguia, Maria Fernández-Saorin, Natalia Jiménez, Ana Senan-Salinas, Carme Solé-Blanch, Andrea Feu, Mercedes Marín-Aguilera, Juan Carlos Pardo, Maria Ochoa-de-Olza, Joan Montero, Begoña Mellado, Albert Font
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Background: Docetaxel remains the standard treatment for metastatic castration-resistant prostate cancer (mCRPC). However, resistance frequently emerges as a result of hyperactivation of the PI3K/AKT and the MEK/ERK pathways. Therefore, the inhibitio
Externí odkaz:
https://doaj.org/article/15a09439b35e4fa08388d66216c30dd7
Autor:
Raquel Carrasco, Mercedes Ingelmo-Torres, Josep Oriola, Fiorella L. Roldán, Leonardo Rodríguez-Carunchio, Sandra Herranz, Begoña Mellado, Antonio Alcaraz, Laura Izquierdo, Lourdes Mengual
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Background and aimsThe spatial and temporal genetic heterogeneity of bladder cancer (BC) makes challenging to find specific drivers of metastatic disease, thus preventing to determine those BC patients at high risk of tumor progression. Our aim was t
Externí odkaz:
https://doaj.org/article/95eac61775564d0fada730a0437a3e60
Autor:
Arlene O. Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donas, Robert A. Huddart, Earle F. Burgess, Mark T. Fleming, Arash Rezazadeh Kalebasty, Begoña Mellado, Sergei Varlamov, Monika Joshi, Ignacio Duran, Scott T. Tagawa, Yousef Zakharia, Keqin Qi, Sydney Akapame, Spyros Triantos, Anne O'Hagan, Yohann Loriot
Publikováno v:
European Urology Open Science, Vol 50, Iss , Pp 1-9 (2023)
Background: Erdafitinib is indicated for the treatment of adults with locally advanced/metastatic urothelial carcinoma and susceptible FGFR3/2 alterations progressing on/after one or more lines of prior platinum-based chemotherapy. Objective: To bett
Externí odkaz:
https://doaj.org/article/859488fb49644ff6bbf4afa1b1012ee4
Autor:
María José Juan Fita, Urbano Anido Herranz, María José Mendez-Vidal, Regina Gironés-Sarrió, José Muñoz-Langa, Juan Sepúlveda-Sánchez, Begoña Mellado, Carlos Alvarez-Fernandez, Lucía Heras López, José Antonio López-Guerrero, Zaida García-Casado, Ana Calatrava, Miguel Ángel Climent
Publikováno v:
Cancers, Vol 15, Iss 21, p 5223 (2023)
The SOGUG-IMANOL trial was a phase 2, uncontrolled, Spanish multicenter study to assess the effect of maintenance treatment with olaparib on radiographic progression-free survival (PFS) in patients with metastatic castration-resistant prostate cancer
Externí odkaz:
https://doaj.org/article/e5e259639d464429b8fe5a204593ff25
Autor:
Elisabet Cantó, Georgia Anguera, Natalia Jiménez, Begoña Mellado, Ona Ramírez, Anais Mariscal, Pablo Maroto, Silvia Vidal
Publikováno v:
Diagnostics, Vol 13, Iss 13, p 2222 (2023)
(1) Background: Prostate cancer is the second most common cancer in men, with androgen suppression as the standard treatment. Despite initially responding to castration, most metastatic prostate cancer patients eventually experience progression. In t
Externí odkaz:
https://doaj.org/article/457c8f8ca5624298ac9e21173ae96619
Autor:
Natalia Jiménez, Òscar Reig, Mercedes Marín-Aguilera, Caterina Aversa, Laura Ferrer-Mileo, Albert Font, Alejo Rodriguez-Vida, Miguel Ángel Climent, Sara Cros, Isabel Chirivella, Montserrat Domenech, Mariona Figols, Enrique González-Billalabeitia, Daniel Jiménez Peralta, Leonardo Rodríguez-Carunchio, Samuel García-Esteve, Marta Garcia de Herreros, Maria J. Ribal, Aleix Prat, Begoña Mellado
Publikováno v:
Cancers, Vol 14, Iss 19, p 4757 (2022)
(1) Background: Androgen deprivation therapy (ADT) and docetaxel (DX) combination is a standard therapy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. (2) Methods: We investigate if tumor transcriptomic analysis predicts mHSPC evo
Externí odkaz:
https://doaj.org/article/dfdd4da0c8db489c9ad7b094fc61256f
Autor:
Natalia Jiménez, Òscar Reig, Ruth Montalbo, Maria Milà-Guasch, Lluis Nadal-Dieste, Giancarlo Castellano, Juan José Lozano, Iván Victoria, Albert Font, Alejo Rodriguez-Vida, Joan Carles, Cristina Suárez, Montserrat Domènech, Núria Sala-González, Pedro Luis Fernández, Leonardo Rodríguez-Carunchio, Sherley Díaz, Aleix Prat, Mercedes Marín-Aguilera, Begoña Mellado
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
The prostatic tumor cells plasticity is involved in resistance to hormone-therapy, allowing these cells to survive despite androgen receptor inhibition. However, its role in taxanes resistance has not been fully established. Gene expression of plasti
Externí odkaz:
https://doaj.org/article/726f1350f86d42a4828178363a9d8ed6
Autor:
Albert Font, Vicenç Ruiz de Porras, Begoña P. Valderrama, Jose Luis Ramirez, Lara Nonell, José Antonio Virizuela, Urbano Anido, Aránzazu González-del-Alba, Nuria Lainez, Maria del Mar Llorente, Natalia Jiménez, Begoña Mellado, Jesus García-Donas, Joaquim Bellmunt
Publikováno v:
Cancers, Vol 13, Iss 24, p 6235 (2021)
In the phase II MAJA trial, maintenance therapy with vinflunine resulted in longer progression-free survival compared to best supportive care in advanced urothelial cell carcinoma (aUCC) patients who did not progress after first-line platinum-based c
Externí odkaz:
https://doaj.org/article/7579d85c0ce840938c9a17ef1c05fa5b
Autor:
Mercedes Marín-Aguilera, María V. Pereira, Natalia Jiménez, Òscar Reig, Anna Cuartero, Iván Victoria, Caterina Aversa, Laura Ferrer-Mileo, Aleix Prat, Begoña Mellado
Publikováno v:
Cancers, Vol 13, Iss 19, p 4960 (2021)
Altered metabolism is a hallmark of cancer. Malignant cells metabolise glutamine to fulfil their metabolic needs. In prostate cancer, androgen receptor signalling promotes glutamine metabolism, which is also involved in cholesterol homeostasis. We ai
Externí odkaz:
https://doaj.org/article/8192d3426d5643a2b1671b33ae6d7ce2
Autor:
Mercedes Marín-Aguilera, Natalia Jiménez, Òscar Reig, Ruth Montalbo, Ajit K. Verma, Giancarlo Castellano, Lourdes Mengual, Iván Victoria, María V. Pereira, Maria Milà-Guasch, Susana García-Recio, Daniel Benítez-Ribas, Raquel Cabezón, Azucena González, Manel Juan, Aleix Prat, Begoña Mellado
Publikováno v:
Cells, Vol 9, Iss 1, p 203 (2020)
Androgen receptor (AR) signaling remains crucial in castration-resistant prostate cancer (CRPC). Since it is also essential in immune cells, we studied whether the expression of AR full-length (ARFL) and its splicing variant ARV7 in peripheral blood
Externí odkaz:
https://doaj.org/article/ca04f526268a4eb6a07d03581c014b50